THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis
出版年份 2018 全文链接
标题
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis
作者
关键词
-
出版物
EUROPEAN JOURNAL OF ENDOCRINOLOGY
Volume 179, Issue 1, Pages R31-R45
出版商
Bioscientifica
发表日期
2018-04-24
DOI
10.1530/eje-18-0056
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rebound vertebral fracture in the dental chair during a tooth extraction whilst on a treatment holiday from denosumab to avoid ONJ!
- (2018) Alexandra Leaney et al. BONE
- Underestimation of Vertebral Fractures After Denosumab Discontinuation
- (2018) Olivier Lamy et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment
- (2017) Athanasios D Anastasilakis et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis
- (2017) J. Y. Reginster et al. EXPERT OPINION ON PHARMACOTHERAPY
- Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis
- (2017) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
- (2017) Steven R Cummings et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
- (2017) Athanasios D Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
- (2017) Bente L Langdahl et al. LANCET
- Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis
- (2017) Felicia Cosman et al. MAYO CLINIC PROCEEDINGS
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
- (2017) Kenneth G. Saag et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates
- (2017) B. Uebelhart et al. OSTEOPOROSIS INTERNATIONAL
- Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
- (2017) T. Lehmann et al. OSTEOPOROSIS INTERNATIONAL
- Observations following discontinuation of long-term denosumab therapy
- (2017) M. R. McClung et al. OSTEOPOROSIS INTERNATIONAL
- Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan
- (2017) T. Mori et al. OSTEOPOROSIS INTERNATIONAL
- Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk
- (2017) M. A. Mignot et al. OSTEOPOROSIS INTERNATIONAL
- Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
- (2017) M. B. Zanchetta et al. OSTEOPOROSIS INTERNATIONAL
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
- (2017) Henry G Bone et al. Lancet Diabetes & Endocrinology
- Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium
- (2017) A. Fahrleitner-Pammer et al. Archives of Osteoporosis
- The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
- (2016) Kosuke Ebina et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)
- (2016) J. N. Tsai et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
- (2016) P. D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis
- (2016) Felicia Cosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Teriparatide and denosumab combination therapy and skeletal metabolism
- (2016) L. Idolazzi et al. OSTEOPOROSIS INTERNATIONAL
- Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
- (2016) M. Kamimura et al. OSTEOPOROSIS INTERNATIONAL
- Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis
- (2016) Bente Langdahl et al. Therapeutic Advances in Musculoskeletal Disease
- The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
- (2015) Dennis M. Black et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate
- (2015) Joy N. Tsai et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate
- (2015) Felicia Cosman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
- (2015) Benjamin Z Leder et al. LANCET
- Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers
- (2015) Athanasios D. Anastasilakis et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Novel therapies for osteoporosis
- (2015) Polyzois Makras et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Denosumab versus zoledronic acid in patients previously treated with zoledronic acid
- (2015) A. D. Anastasilakis et al. OSTEOPOROSIS INTERNATIONAL
- Overlapping and Continued Alendronate or Raloxifene Administration in Patients on Teriparatide: Effects on Areal and Volumetric Bone Mineral Density-The CONFORS Study
- (2014) Christian Muschitz et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
- (2014) Aliya A Khan et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?
- (2014) Felicia Cosman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
- (2014) Benjamin Z. Leder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- An Open-Label, Prospective Pilot Clinical Study of Denosumab for Severe Hyperparathyroidism in Patients With Low Bone Mass Undergoing Dialysis
- (2014) Chien-Liang Chen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-Response–Based Meta-Analysis
- (2014) Jaap W. Mandema et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Risk of Atypical Femoral Fracture during and after Bisphosphonate Use
- (2014) Jörg Schilcher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review
- (2013) Erik F. Eriksen et al. BONE
- Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
- (2013) C. Roux et al. BONE
- Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis
- (2013) Polyzois Makras et al. CLINICAL ENDOCRINOLOGY
- Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
- (2013) Joy N Tsai et al. LANCET
- Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy
- (2013) Chris Recknor et al. OBSTETRICS AND GYNECOLOGY
- Safety issues with bisphosphonate therapy for osteoporosis
- (2013) E. Suresh et al. RHEUMATOLOGY
- Osteoporosis in the European Union: medical management, epidemiology and economic burden
- (2013) E. Hernlund et al. Archives of Osteoporosis
- Bisphosphonate Drug Holiday: Choosing Appropriate Candidates
- (2013) Cynthia Ro et al. Current Osteoporosis Reports
- Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US
- (2013) Anju Parthan et al. Applied Health Economics and Health Policy
- A single-dose study of denosumab in patients with various degrees of renal impairment
- (2012) Geoffrey A Block et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Comparative Effectiveness of Drug Treatments to Prevent Fragility Fractures: A Systematic Review and Network Meta-Analysis
- (2012) Mohammad Hassan Murad et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Bisphosphonates for Osteoporosis — Where Do We Go from Here?
- (2012) Marcea Whitaker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Nitroglycerin Ointment on Bone Density and Strength in Postmenopausal Women
- (2011) Sophie A. Jamal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
- (2011) Dennis M Black et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover
- (2011) Richard Eastell et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
- (2011) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Denosumab and bisphosphonates: Rivals or potential “partners”? A “hybrid” molecule hypothesis
- (2011) Athanasios D. Anastasilakis et al. MEDICAL HYPOTHESES
- Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study
- (2011) P. D. Miller et al. OSTEOPOROSIS INTERNATIONAL
- Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension
- (2011) G. Bianchi et al. OSTEOPOROSIS INTERNATIONAL
- Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
- (2011) N. Freemantle et al. OSTEOPOROSIS INTERNATIONAL
- Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium
- (2011) Mickaël Hiligsmann et al. PHARMACOECONOMICS
- Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget’s disease of bone
- (2010) Stergios A. Polyzos CLINICAL RHEUMATOLOGY
- Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial
- (2010) Ann V Schwartz et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis
- (2010) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis
- (2010) Joel S. Finkelstein et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial
- (2010) Paul D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- RANKL inhibition for the management of patients with benign metabolic bone disorders
- (2009) Athanasios D Anastasilakis et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis
- (2009) A. D. Anastasilakis et al. HORMONE AND METABOLIC RESEARCH
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
- (2009) David L Kendler et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo
- (2009) Anke J Roelofs et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
- (2008) Paul D. Miller et al. BONE
- Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study*
- (2008) Helmut Minne et al. CURRENT MEDICAL RESEARCH AND OPINION
- Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
- (2008) Ann E. Kearns et al. ENDOCRINE REVIEWS
- Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*
- (2008) Jacques P Brown et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate
- (2008) Paul D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data
- (2008) A. Cranney et al. OSTEOPOROSIS INTERNATIONAL
- Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis
- (2008) Socrates Papapoulos et al. Nature clinical practice. Endocrinology & metabolism
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started